The U.S. Food and Drug Administration (FDA) has given the green light to Citius Pharmaceuticals’ new therapy, Lymphir, for treating a rare form of blood cancer known as cutaneous T-cell lymphoma. This approval comes a year after the FDA initially rejected the treatment.

Key Details

• Treatment Overview
  • Name: Lymphir
  • Type: Therapy for cutaneous T-cell lymphoma
  • Target Patients: Adults with relapsed cutaneous T-cell lymphoma who have received at least one prior treatment
  • Prevalence: About 2,500 to 3,000 new cases annually in the U.S.
• Approval and Launch
  • Initial Rejection: July of the previous year due to a need for additional testing data
  • Launch Timeline: Planned within the next five months
  • Pricing: Expected to be in line with existing market treatments
• Safety Concerns
  • Boxed Warning: The FDA’s prescribing information includes a serious warning for capillary leak syndrome, a rare condition that causes blood plasma to leak from small blood vessels and results in a rapid drop in blood pressure.
• Market Context
  • Existing Treatments: Includes Bristol Myers Squibb’s Istodax and Bausch Health’s Targretin
  • Company’s Response: CEO Leonard Mazur expressed confidence that the boxed warning will not significantly hinder the therapy’s adoption, as both patients and physicians are aware of the risks.
• Company Plans
  • New Launch Unit: Lymphir will be introduced through Citius Oncology, which is set to go public soon through a SPAC deal.

The U.S. Food and Drug Administration (FDA) has approved ARS Pharmaceuticals’ new nasal spray, neffy, as an alternative to the traditional EpiPen for emergency allergic reactions. This approval marks the first needle-free treatment for potentially fatal allergic reactions.

Key Details

• Product Overview
  • Name: Neffy
  • Form: Nasal spray
  • Use: Single-dose spray administered into one nostril
  • Target Users: Approved for both adults and pediatric patients weighing at least 30 kilograms
• Availability and Pricing
  • Expected Release: Within eight weeks of FDA approval
  • Price: $199 for two doses through digital pharmacy sites like BlinkRx and GoodRx for uninsured patients
  • Co-Pay Savings: Some commercially insured patients can obtain neffy for $25 per prescription through a co-pay savings program
• Benefits and Accessibility
  • Needle-Free: Offers a non-injection alternative to EpiPen and other autoinjectors filled with epinephrine
  • Reduced Barriers: Aims to make treatment more accessible for those who fear needles, particularly children
• Medical Context
  • Condition: Anaphylaxis is a severe, life-threatening allergic reaction that affects multiple parts of the body and requires immediate medical attention.

Kelly Stone, an associate director at the FDA’s Center for Drug Evaluation and Research, highlighted that the nasal spray could help overcome reluctance to use injectable treatments, potentially improving access to life-saving medication.

Eli Lilly’s strong second-quarter performance has exceeded expectations, driven by booming sales of its diabetes medication Mounjaro and weight loss injection Zepbound. The company has significantly raised its revenue outlook and reported a substantial increase in earnings.

Key Highlights

• Earnings and Revenue
  • Earnings per Share (EPS): $3.92 (adjusted), surpassing the $2.60 forecast.
  • Revenue: $11.30 billion, exceeding the $9.92 billion estimate.
  • Net Income: $2.97 billion ($3.28 per share), up from $1.76 billion ($1.95 per share) a year earlier.
• Revenue Outlook
  • Eli Lilly has increased its full-year revenue guidance to between $45.4 billion and $46.6 billion, up by $3 billion at both ends of the range.
  • The company also raised its full-year adjusted earnings forecast to $16.10 to $16.60 per share, from the previous range of $13.50 to $14 per share.
• Drug Sales
  • Mounjaro: Generated $3.09 billion in sales, more than triple the amount from the same period last year. Analysts had expected $2.39 billion.
  • Zepbound: Achieved $1.24 billion in sales, well above the anticipated $922.2 million.
• Supply and Demand
  • Despite previous supply issues, all doses of Zepbound and Mounjaro are now available in the U.S. after extended shortages.
  • Eli Lilly has ramped up production, with plans to increase output of incretin drugs by 50% in the latter half of 2024 compared to the previous year.
• Future Outlook
  • Eli Lilly is working on developing more convenient weight loss pills to meet growing demand.
  • The company has built six new manufacturing plants and hired thousands of workers to boost production.
• Stock Performance
  • Shares of Eli Lilly closed over 9% higher on Thursday and have risen more than 30% this year, following a nearly 60% increase in 2023.

Market Context

Eli Lilly’s success with Mounjaro and Zepbound contrasts with challenges faced by competitors. Novo Nordisk reported weaker-than-expected sales for its weight loss drug Wegovy and diabetes injection Ozempic, partly due to pricing pressures.